ConcertAI and NeoGenomics join forces to advance hematologic research through integration of real-world data and AI technologies

ConcertAI, a leader in oncology real-world data (RWD), real-world evidence (RWE) and AI technology, has partnered with NeoGenomics, a prominent oncology testing services company, to advance large-scale hematologic research solutions. This collaboration is designed to address critical challenges in hematologic malignancy research, and leverages robust RWD and advanced analytics to achieve this.

Hematologic malignancies present unique challenges compared to solid tumors, demanding diverse treatment approaches and meticulous disease monitoring. The collaboration seeks to overcome these complexities by combining ConcertAI’s rich longitudinal clinical data with NeoGenomics’ comprehensive library of biomarkers derived from hundreds of hematologic tests. This will allow for the creation of an extensive RWE hematology dataset, encompassing over one million patient lives across more than 1000 oncology clinics.

The collaboration will address historical limitations in hematologic data, paving the way for significant advancements in cancer research, clinical trials, and improved patient outcomes.

“ConcertAI has spent the last three years with biopharma researchers, medical societies, patient advocacy groups, and academic teams to define requirements for truly definitive, insight-enabling research solutions for hematologic malignancies,” emphasized Jeff Elton, CEO of Concert AI, ”We did this with the collective goal of having a decade or more of data, richness, consistency in biomarker coverage and the ability to integrate across clinical data and diagnostic modalities. NeoGenomics captures the majority of all US hematologic malignancy testing being sent out to a reference laboratory. It was obvious to both teams that combining our data and capabilities could solve the legacy challenges of depth, breadth, and limited longitudinality.”

The resulting population-scale hematology dataset minimizes selection bias and accurately reflects the landscape of prevalent hematologic diseases in the US. The collaboration integrates electronic medical record (EMR) data with rich biomarker information, enabling advanced causal inference methodologies and clinically relevant AI approaches.

Lindsey Gasparini, Vice President of Informatics at NeoGenomics, emphasized the impact of this collaboration, “We are excited to see the collaboration produce a rich and meaningful dataset to fuel life science research, clinical trial planning and RWD application. Our expansive footprint in hematologic testing will enable an important view into clinical work up, diagnosis, and monitoring through longitudinal and multi-modal testing for the community oncologist. ConcertAI has an impressive collection of research-grade clinical data in oncology and hematology, and the power in linking that with the depth and breadth of NeoGenomics data is transformational.”

The resulting data richness enables exploration using advanced generative AI applications and other complementary approaches that were historically constrained by limited data sizes and standardization. As a result, the companies plan to launch a hematology-focused version of ConcertAI’s Clinical Trial Optimization solution in Q1 2024, facilitating optimal study design and trial planning.